Sectra shares jump 9% on strong order bookings, cash flow in FY report

Sectra shares jumped over 9% following a report of strong fiscal year 2024/2025 results, including a 39.9% increase in contracted order bookings to SEK 8.71 billion and a 182.7% surge in cash flow from operations to SEK 922.4 million. Net sales grew 9.3% to SEK 3.24 billion, driven by a 19.9% increase in recurring revenue, and the company proposed a total dividend of SEK 2.10 per share. The company cited higher demand for medical imaging IT systems and secure communication services as contributing factors to the growth.

Analysis

Sectra (SECTb) reported a robust fiscal year 2024/2025, highlighted by a 39.9% increase in contracted order bookings to SEK 8.71 billion and a 137.7% surge in guaranteed order bookings to SEK 7.65 billion, significantly bolstering future revenue visibility. Net sales grew 9.3% to SEK 3.24 billion, powerfully supported by a 19.9% rise in recurring revenue, which now accounts for 63.8% of total sales, and an impressive 48.9% expansion in cloud recurring revenue to SEK 591.1 million. Operating profit increased by 39.6% to SEK 723 million; excluding a one-time SEK 110 million patent settlement, operating profit still advanced a healthy 18.4% to SEK 613 million, yielding an operating margin of 18.9%. Cash flow from operations demonstrated exceptional strength, surging 182.7% to SEK 922.4 million. While fourth-quarter net sales growth was more tempered at 1.8% and operating profit up 0.8%, Q4 contracted order bookings soared by 223.4%, indicating sustained high demand for Sectra's medical imaging IT systems and secure communication services. The market reacted positively to these results, with Sectra's shares jumping over 9%.

Key Decisions for Investors

• Consider the strong growth in order bookings and recurring revenue, especially from cloud services, as supportive of a positive investment outlook, despite the recent share price appreciation.
• Monitor the conversion of the significant order backlog into sustained top-line growth and margin improvement in future quarters, particularly given the more moderate Q4 net sales increase.
• Evaluate the proposed total dividend of SEK 2.10 per share, including an extraordinary dividend, as an additional component of shareholder return, supplementing the company's primary growth narrative in medical IT and cybersecurity.